Biopsies: next-generation biospecimens for tailoring therapy
Authors:
- 25 June 2013
- journal article
- review article
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 10 (8) , 437-450
Abstract
The majority of samples in existing tumour biobanks are surgical specimens of primary tumours. Insights into tumour biology, such as intratumoural heterogeneity, tumour–host crosstalk, and the evolution of the disease during therapy, require biospecimens from the primary tumour and those that reflect the patient's disease in specific contexts. Next-generation 'omics' technologies facilitate deep interrogation of tumours, but the characteristics of the samples can determine the ultimate accuracy of the results. The challenge is to biopsy tumours, in some cases serially over time, ensuring that the samples are representative, viable, and adequate both in quantity and quality for subsequent molecular applications. The collection of next-generation biospecimens, tumours, and blood samples at defined time points during the disease trajectory—either for discovery research or to guide clinical decisions—presents additional challenges and opportunities. From an organizational perspective, it also requires new additions to the multidisciplinary therapeutic team, notably interventional radiologists, molecular pathologists, and bioinformaticians. In this Review, we describe the existing procedures for sample procurement and processing of next-generation biospecimens, and highlight the issues involved in this endeavour, including the ethical, logistical, scientific, informational, and financial challenges accompanying next-generation biobanking.Keywords
This publication has 129 references indexed in Scilit:
- Ultradense Array CGH and Discovery of Micro-Copy Number Alterations and Gene Fusions in the Cancer Genome2013
- Comprehensive molecular characterization of human colon and rectal cancerNature, 2012
- Toward a roadmap in global biobanking for healthEuropean Journal of Human Genetics, 2012
- Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancerNature, 2012
- Biopsy of liver metastasis for women with breast cancer: Impact on survivalThe Breast, 2012
- The Life History of 21 Breast CancersCell, 2012
- Managing incidental findings and research results in genomic research involving biobanks and archived data setsGenetics in Medicine, 2012
- Raise standards for preclinical cancer researchNature, 2012
- The Genetic Basis for Cancer Treatment DecisionsCell, 2012
- Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)Breast Cancer Research and Treatment, 2011